|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-1.38/-2.51
|
企业价值
365.49M
|
资产负债 |
每股账面净值
4.08
|
现金流量 |
现金流量率
--
|
损益表 |
收益
34.48M
|
每股收益
0.38
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/04/29 04:19 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPRplatform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipelineof allogeneic CAR-T and CAR-NK cell therapies. |